Broadfin Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Broadfin Capital’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-98,700	Closed	-$1.62M	–	101
2015 Q3	$1.62M	Sell	98,700 -184,633	-65%	-$3.79M	0.09%	84
2015 Q2	$6.36M	Sell	283,333 -300,000	-51%	-$4.75M	0.34%	64
2015 Q1	$5.71M	Buy	583,333 +250,000	+75%	+$2.45M	0.44%	56
2014 Q4	$3.8M	Buy	333,333 +83,333	+33%	+$904K	0.33%	59
2014 Q3	$2.88M	Buy	+250,000	New	+$3.82M	0.3%	63

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Broadfin Capital's CASC Position: Q4 2015 in Review

Broadfin Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 98,700 shares — an estimated $1.62M sold.

Broadfin Capital first reported a position in CASC in Q3 2014 and held it in 5 quarters. The position peaked at $6.36M in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

Broadfin Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Broadfin Capital sold 98,700 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $1.62M.
Broadfin Capital first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 5 quarters.
Broadfin Capital's Cascadian Therapeutics, Inc. position peaked at $6.36M in Q2 2015.
93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Broadfin Capital's 13F filing for Q4 2015, filed 16 Feb 2016.